StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cartesian Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$76.53M. For fiscal 2025 it was -$73.94M. The highest annual figure on record is $34.88M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$73.94M–
FY2024Dec 31, 2024-$23.67M–
FY2023Dec 31, 2023-$51.16M–
FY2022Dec 31, 2022-$31.63M–
FY2021Dec 31, 2021-$60.38M-273.1%
FY2020Dec 31, 2020$34.88M–
FY2019Dec 31, 2019-$51.44M–
FY2018Dec 31, 2018-$59.16M–
FY2017Dec 31, 2017-$52.03M–
FY2016Dec 31, 2016-$19.76M–
FY2015Dec 31, 2015-$22.46M–
FY2014Dec 31, 2014-$12.69M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.08M–
Q1 FY2026Mar 31, 2026-$22.14M–
Q4 FY2025Dec 31, 2025-$17.71M–
Q3 FY2025Sep 30, 2025-$15.60M-213.9%
Q2 FY2025Jun 30, 2025-$17.52M–
Q1 FY2025Mar 31, 2025-$23.11M–
Q4 FY2024Dec 31, 2024-$7.00M–
Q3 FY2024Sep 30, 2024$13.69M–
Q2 FY2024Jun 30, 2024-$14.45M–
Q1 FY2024Mar 31, 2024-$15.92M–
Q4 FY2023Dec 31, 2023-$23.29M–
Q3 FY2023Sep 30, 2023-$9.22M-311.7%
Q2 FY2023Jun 30, 2023-$9.90M–
Q1 FY2023Mar 31, 2023-$8.77M–
Q4 FY2022Dec 31, 2022-$11.85M–
Q3 FY2022Sep 30, 2022$4.35M–
Q2 FY2022Jun 30, 2022-$12.27M–
Q1 FY2022Mar 31, 2022-$11.86M–
Q4 FY2021Dec 31, 2021-$31.46M–
Q3 FY2021Sep 30, 2021-$10.75M-116.4%
Q2 FY2021Jun 30, 2021-$6.04M–
Q1 FY2021Mar 31, 2021-$12.13M–
Q4 FY2020Dec 31, 2020-$7.25M–
Q3 FY2020Sep 30, 2020$65.64M–
Q2 FY2020Jun 30, 2020-$11.81M–
Q1 FY2020Mar 31, 2020-$11.70M–
Q4 FY2019Dec 31, 2019-$12.88M–
Q3 FY2019Sep 30, 2019-$11.12M–
Q2 FY2019Jun 30, 2019-$7.20M–
Q1 FY2019Mar 31, 2019-$20.24M–
Q4 FY2018Dec 31, 2018-$12.75M–
Q3 FY2018Sep 30, 2018-$16.03M–
Q2 FY2018Jun 30, 2018-$16.97M–
Q1 FY2018Mar 31, 2018-$13.41M–
Q4 FY2017Dec 31, 2017-$12.66M-954.3%
Q3 FY2017Sep 30, 2017-$15.44M–
Q2 FY2017Jun 30, 2017-$8.61M–
Q1 FY2017Mar 31, 2017-$15.32M–
Q4 FY2016Dec 31, 2016$1.48M–
Q3 FY2016Sep 30, 2016-$5.47M–

More Cartesian Therapeutics figures

See a number that looks wrong?